@Article{,
AUTHOR = {Fred Saad, Paul Perrotte, François Bénard, Michael McCormack, Pierre I. Karakiewicz},
TITLE = {Bone health in men with prostate cancer: diagnostic and therapeutic considerations},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {12},
YEAR = {2005},
NUMBER = {Suppl.3},
PAGES = {9--15},
URL = {http://www.techscience.com/CJU/v12nSuppl.3/63362},
ISSN = {1488-5581},
ABSTRACT = {With current treatments, men usually survive many
years after being diagnosed with prostate cancer.
However, the systemic effects of prostate cancer and
therapies such as androgen deprivation therapy (ADT)
can undermine skeletal integrity, resulting in skeletal
complications that may erode quality of life (QOL).
Prostate cancer patients are at risk for fractures from
cancer treatment-induced bone loss. In addition, they
are also at risk for pathologic fractures, severe bone pain,
and other sequelae from bone metastases, which almost
invariably occur during the progression of prostate cancer.
This review investigates the incidence and
pathophysiology of bone loss and skeletal morbidity in
prostate cancer patients and reviews available treatment
options for maintaining skeletal health throughout the
continuum of care for these patients. Several supportive
interventions are available to prevent generalized and
localized bone loss, including calcium and vitamin D
supplements and bisphosphonates. Oral calcium and
vitamin D supplementation alone, however, appears to
be insufficient to prevent bone loss during ADT. New
generation bisphosphonates such as zoledronic acid can
prevent bone loss for patients on ADT and can reduce
skeletal morbidity for those with bone metastases.},
DOI = {}
}